Collagen-producing eye cell atlas reveals distinct fibroblast fates in early injury vs. fibrotic subretinal disease
Abstract
Fibrosis is the end-stage of a maladaptive process that occurs when the body’s normal wound-healing strategy becomes dysregulated. Subretinal fibrosis is the end stage of neovascular age-related macular degeneration (nAMD), the most common cause of central vision loss in people over the age of 50. The cellular sources of excess extracellular matrix (ECM) contributing to subretinal fibrosis are unknown, as is the heterogeneity of cells involved in the fibrotic process. Here we identify cells contributing to subretinal fibrosis by using Col1a1 -YFP reporter mice to noninvasively image collagen production in real-time in vivo in two disease models, 1) a resolving retinal injury model and 2) a fibrotic model of subretinal disease. We create a collagen-producing eye cell atlas for subretinal injury and demonstrate subretinal fibroblast heterogeneity in healthy, resolving, and fibrotic tissue. We identify distinct molecular characteristics of general repair/resolving fibroblast populations versus pathogenic pro-fibrotic collagen-producing fibroblasts. Integration of this collagen-producing eye cell atlas with a published collagen-producing lung cell atlas shows conserved pro-fibrotic fibroblasts in both organs, yet also uncovers tissue-specific fibroblast populations unique to subretinal fibrosis. A Fap + Fgl2 + fibroblast population significantly expands in subretinal fibrosis that expresses the highest levels of collagens and distinctively expresses ECM components Periostin , Col15a1 and Col6a5 . Immunolabeling of mouse and human-donor eye tissue support the fibroblastic expression and perivascular location of periostin as clearly distinguishing between bona fide fibrosis and early disease in nAMD. Our collagen-producing eye cell atlas is a valuable resource for studying distinct fibroblast subsets in homeostasis, early injury, and fibrosis.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (15)
Ema Ozaki
Department of Clinical Medicine, School of Medicine, Trinity College Dublin
Said Aktas
Pharma Research and Early Development, Roche Innovation Center Zurich, Roche Glycart AG.
Kelly Mulfaul
Department of Neuroscience and Pharmacology, University of Iowa
Kiva Brennan
Department of Clinical Medicine, School of Medicine, Trinity College Dublin
Christophe Roubeix
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
Sarah Palko
Department of Clinical Medicine, School of Medicine, Trinity College Dublin
Katie Robb
Department of Clinical Medicine, School of Medicine, Trinity College Dublin
Tai-Hsien Ou Yang
Roche Pharma Research and Early Development, Data and Analytics, Roche Translational & Clinical Research Center, F. Hoffmann-La Roche Ltd.
Marie-Claire Schanne-Klein
Laboratoire d’Optique et Biosciences, Ecole Polytechnique, CNRS, INSERM, Institut Polytechnique de Paris
Anna Toidze
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
Avril Watson
Department of Clinical Medicine, School of Medicine, Trinity College Dublin
Mark Cahill
Progressive Vision Research
Peter D. Westenskow
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
Derrick Feenstra
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.
Sarah L. Doyle
Department of Clinical Medicine, School of Medicine, Trinity College Dublin